key: cord-0886709-1vyfy7i0
authors: Vanshylla, Kanika; Fan, Chengcheng; Wunsch, Marie; Poopalasingam, Nareshkumar; Meijers, Matthijs; Kreer, Christoph; Kleipass, Franziska; Ruchnewitz, Denis; Ercanoglu, Meryem S.; Gruell, Henning; Münn, Friederike; Pohl, Kai; Janicki, Hanna; Nolden, Tobias; Bartl, Simone; Stein, Saskia Catherina; Augustin, Max; Dewald, Felix; Gieselmann, Lutz; Schommers, Philipp; Schulz, Thomas F.; Sander, Leif Erik; Koch, Manuel; Luksza, Marta; Lässig, Michael; Bjorkman, Pamela J.; Klein, Florian
title: Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
date: 2021-12-18
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.12.010
sha: ffe7d30806fdf53ddc62da35ae203f82d8fa5cc4
doc_id: 886709
cord_uid: 1vyfy7i0

A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we performed single B-cell analysis from 10 SARS-CoV-2 elite neutralizers. We isolated and analyzed 126 monoclonal antibodies, many of which were sarbecovirus cross-reactive, with some displaying merbecovirus- and embecovirus-reactivity. Several isolated broadly neutralizing antibodies were effective against B.1.1.7, B1.351, B.1.429, B.1.617, B.1.617.2 variants and 19 prominent potential escape sites. Furthermore, assembly of 716,806 SARS-CoV-2 sequences predicted emerging escape variants, which were also effectively neutralized. One of these broadly neutralizing potent antibodies, R40-1G8, is a IGHV3-53 RBD-Class-1 antibody. Remarkably, Cryo-EM analysis revealed that R40-1G8 has a flexible binding mode, targeting both ‘up’ and ‘down’ conformations of the RBD. Given the threat of emerging SARS-CoV-2 variants, we demonstrate that elite neutralizers are a valuable source for isolating ultrapotent antibody candidates to prevent and treat SARS-CoV-2 infection.

In order to functionally analyze the SARS-CoV-2 antibody response of elite neutralizers, we 170 cloned and produced 126 monoclonal antibodies, representing different heavy and light chain 171 gene combinations including IgHV3-30 (16.6%), IgHV1-69 (9.5%), IgHV3-30-3 (7.9%), IgHV3-172 53 (11.1%) and IgKV3-20 (19%), IgKV1-9 (11.9%) and IgLV1-40 (6.3%) ( Figure S2B) . All 173 antibodies were tested in ELISA for reactivity against the SARS-CoV-2 trimer, RBD, S1 and 174 S2 domains, as well as SARS-1, MERS, HKU-1 and OC43 spike proteins ( Figure 3A ).

Neutralizing activity against SARS-CoV-2 was determined by using a spike-based pseudovirus 176 assay ( Figure 3A ) as well as authentic virus assay ( Figure S2C ). In addition, neutralizing 177 activity against SARS-CoV-1 and the Bat CoV WiV1, that share the same receptor and high 178 sequence similarity with SARS-CoV-2 (Hoffmann et al., 2020a) was tested in pseudovirus 179 assays ( Figure 3A ).

The majority of mAbs (42.8%) were directed against the RBD, while 38.9% bound to the S2 181 region and 12.7% of mAbs bound the S1 outside the RBD, only 4 out of 126 antibodies did not 182 bind to the SARS-CoV-2 spike by ELISA (Figures 3A and 3B) . Neutralizing 

In summary, our evaluation of the isolated NAbs from elite neutralizers revealed a large pool 233 of highly potent SARS-CoV-2 bNAbs that exhibit full coverage against the most prevalent 234 variants of concern as well as RBD escape sites with retention of potent neutralizing activity 235 against the spike. 

This was used to obtain frequencies for the VoCs and RBD mutants ( Figure 5A, 5B) , as well 244 as frequency trajectories from October 2020 onwards ( Figure S4A ). Global frequencies were 245 also compared to frequencies in regions with high (>60%) or low (<30%) vaccination rates 246 ( Figure S4A) . Here, no substantial differences in trajectories were observed except the B. 

To pin down the binding mode, we selected one of the most potent and broad bNAbs from the 284 pool with overlapping RBD binding for Cryogenic electron microscopy (cryo-EM) analysis 285 (Figure 6 and S5) . The selected bNAb, R40-1G8, is an IGHV3-53/IGKV1-9 antibody with an 286 IC50 of 0.001 g/ml against the Wu01 spike and average IC50 of 0.004 g/ml across the variant 287 panel (Figure 4) . To define the binding epitope, we determined a single-particle cryo-EM 288 structure of SARS-CoV-2 S 6P trimer in complex with R40-1G8 Fab in two conformational 289 states of the RBD (Figure 6A, B) . R40-1G8 Fab was found to bind to both up (state 1) and 290 down (state 2) RBDs but due to the relative low resolution for the RBD and Fab in state 2 291 ( Figure S5) , we only built the model for state 1 with R40-1G8 Fab bound to all up RBDs.

Focused refinement of the region of RBD of SARS-CoV-2 S 6P trimer bound R40-1G8 resulted 293 in a 3.5 Å local resolution ( Figure S5) . The interaction between R40-1G8 and the RBD is 294 mainly mediated through the heavy chain contacting 16 residues and the light chain having 5 295 J o u r n a l P r e -p r o o f 12 sites of contact ( Figure 6D, 6E) . Structural alignments with complex structures of class 1 296 (C102 and C105) and class 2 (C002) revealed that R40-1G8 binds to similar epitope as C102 297 or C105, suggesting it is a class 1 antibody (Figure 6F and S6) .

C102 is a class 1 antibody encoded by the IGHV3-53 gene that binds the RBD only in an 'up' 299 conformation (Barnes et al., 2020) . R40-1G8 seem to be an exception in the class-1 RBD 300 antibody class as it binds both an 'up' and 'down' RBD conformation (Figure 5, S5 and S6) .

In addition, many IGHV3-53 antibodies like C102 with a short CDRH3 are affected by the K417 (Table S2) , R40-1G8 is not affected by the K417E/N/T mutation 304 which is a prominent escape site found in VoCs like B.1.351 (Figure 4 and S6) . The K417 site 305 in the C102 structure is almost forming a cation-pi interaction in addition to a hydrogen bonding 306 interaction. However, K417 in the R40-1G8 structure does not have this interaction, which 307 explains lack of escape at this residue ( Figure S6 ). R40-1G8 is also not affected by another 308 key mutation at N501Y, which is present in the VoC B.1.1.7 as the antibody can accommodate 309 Y at RBD position 501 ( Figure S6 ). In summary, by examining structural binding properties of 310 R40-1G8, we found a class-1 RBD antibody binding mechanism which encompasses binding 311 to both 'up' and 'down' RBD, thereby providing structural insights into the high potency and 312 breadth of the bNAb.

Discussion 315 SARS-CoV-2 elite neutralizers mount a highly potent NAb response following natural infection, 316 which is accompanied by the presence of cross-reactive antibodies against other closely 317 related -CoVs (Vanshylla et al., 2021) . The mAb response in such individuals has not been 318 studied in detail and could prove to be a critical source of potent neutralizing antibodies as 319 therapeutics to treat or prevent SARS-CoV-2 infection. In this study, we isolated mAbs from 320 10 elite neutralizers that were identified from screening of 963 COVID-19 convalescent 321 J o u r n a l P r e -p r o o f 13 individuals. We discovered, several ultrapotent RBD-directed antibodies that potently 322 neutralize prevalent VoCs and a panel of prominent RBD escape mutants, and also an S2-323 directed neutralizing antibody with cross-reactivity spanning the sarbecovirus, merbecovirus 324 and embecovirus family. Importantly, the isolated bNAbs are able to neutralize all variants of 325 concern as well as emerging variants. 358 Weisblum et al., 2020) . The prediction of escape sites by using frequency trajectories and 359 building a phylogenetic-tree using 700,000 sequences helps study variants that are circulating 360 low levels but might expand in the near future. Therefore, by testing such sites, we predict that 361 the isolated bNAbs are likely to cover variants that may arise in the near future. Other ** R568-2E7 shows altered kinetics in spike variants with D614G mutation. **>5 μg/ml (REGN NAbs) highest tested concentration. R 2 0 7 -2 F 1 1 R 4 0 -1 G 8 R 5 6 8 -2 G 5 R 5 6 8 -2 B 1 1 R 2 0 7 -2 G 4 R 4 0 -1 C 8 R 5 6 8 -2 B 9 R 5 6 8 -1 G 9 R 1 2 1 -1 F 1 R 2 5 9 -1 B 9 D z if 1 0 c R E G N 1 0 9 3 3 R E G N 1 0 9 8 7 C 1 0 2 P 2 B -2 F 6 S 3 0 9 F a b 2 -3 6 neutralizers on a single B-cell level. Isolated antibodies were highly potent and neutralized various mutants including the predominant variants of concern and emerging variants. Structural analysis of one ultrapotent IGHV3-53/IGKV1-9 bNAb revealed a flexible binding mechanism to the RBD.

W iV -1 P S V R40-1A1 R40-1A10 R40-1A8 R40-1B4 R40-1B9 R40-1C8 R40-1D3 R40-1D4 R40-1E1 R40-1E4 R40-1G12 R40-1G6 R40-1G8 R40-1H4 R121-1B5 R121-1C10 R121-1D2 R121-1F1 R121-3A3 R121-3B8 R121-3C12 R121-3F1 R121-3F11 R121-3F7 R121-3G10 R121-3G2 R121-3H4 R121-3H6 R200-1B8 R200-1B9 R200-1E4 R200-1F9 R200-1G11 R200-4A7 R200-4C1 R200-4C6 R200-4E3 R200-4E9 R200-4F4 R207-1C1 R207-1C4 R207-1G1 R207-1G10 R207-2A10 R207-2A5 R207-2A6 R207-2C2 R207-2F11 R207-2F12 R207-2G4 R207-2H1 R259-1A4 R259-1B9 R259-1F2 R259-1F4 R259-3A5 R259-3A6 R259-3C6 R259-3D1 R259-3D2 R259-3E12 R259-3E7 R259-3F2 R259-3G9 R339-1A1 R339-1A4 R339-1B11 R339-1D5 R339-1F5 R339-1G10 R339-3A7 R339-3B5 R339-3B6 R339-3C6 R339-3G4 R410-1A8 R410-1B8 R410-1C7 R410-1D8 R410-1H2 R410-3A10 R410-3D10 R410-3E11 R410-3F2 R410-3G12 R410-3G3 R410-3H9 R568-1A9 R568-1B3 R568-1C6 R568-1E8 R568-1G9 R568-2A1 R568-2A3 R568-2A9 R568-2B11 R568-2B9 R568-2E1 R568-2E7 R568-2F1 R568-2G11 R568-2G5 R616-1A11 R616-1A12 R616-1A2 R616-1A7 R616-1A9 R616-1B6 R616-1C7 R616-1D10 R616-1D2 R616-1D6 R616-1E6 R616-1F10 R616-1G4 R616-1G8 R849-1C11 R849-1C4 R849-1D7 R849-1F9 R849-1G7 R849-1H1 R849-3A9 R849-3B4 R849-3D8 R849-3H2 CR200-1B9 R207-2F11 R40-1G8 R568-2G5 R568-2B11 R207-2G4 R40-1C8 R568-2B9 R568-1B3 R568-2E1 R568-1G9 R121-1F1 R259-1B9 R121-3G2 R568-2F1 R40-1B4 R40-1E1 R849-1C11 R568-2E7 R40-1E4 R40-1G6 R410-1A8 R339-3B5 R200-1F9 R568-2G11 R207-2A6 R40-1D3 R568-1A9 R40-1A8 R207-2C2 R200-1B8 R207-1C4 R339-1B11 R207-2A10 R40-1H4 R207-2H1 R200-4F4 R849-1H1 R207-1G1 R849-3H2 R121-3F11 R207-1C1 R40-1B9 R568-1E8 R568-2A3 R339-3C6 R849-1G7 R200-1G11 R616-1F10 R616-1A11 R568-1C6 R40-1G12 R568-2A1 R40-1A1 R616-1G4 R616-1D6 R121-3F7

Broad betacoronavirus neutralization 1001 by a stem helix-specific human antibody

CoV-2 variant Delta to antibody neutralization

Pause in the Distribution of bamlanivimab/etesevimab. 1006 phegov

cryoSPARC: algorithms 1009 for rapid unsupervised cryo-EM structure determination

Convergent antibody responses to 1012 SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and 1015 protection from disease in a small animal model

Antigen-Specific Adaptive Immunity 1018 to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

TreeTime: Maximum-likelihood 1021 phylodynamic analysis

Structural basis for broad 1024 coronavirus neutralization

SARS-CoV-2 RBD antibodies that maximize 1027 breadth and resistance to escape

Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR 1034 and expression vector cloning

Kinetics and correlates of 1037 the neutralizing antibody response to SARS-CoV-2 infection in humans

Evaluating the Effects of SARS-CoV-2 Spike 1041

Sequencing and cloning of antigen-specific antibodies from mouse 1044 memory B cells

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

REGN-COV2, a Neutralizing Antibody Cocktail, in 1053 Outpatients with Covid-19

Escape from neutralizing 1056 antibodies by SARS-CoV-2 spike protein variants

An Alternative Binding Mode

Antibodies to the SARS-CoV-2 Receptor Binding Domain

IgBLAST: an immunoglobulin variable 1064 domain sequence analysis tool

Structural and functional ramifications of antigenic drift in 1067 recent SARS-CoV-2 variants

Structural basis of a shared antibody response to SARS-CoV-2

Dissecting antibody-mediated protection against SARS-CoV-1072 2

Rapid isolation and profiling of a diverse panel 1075 of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

IGHV gene 1 -5 8 1 -5 8 1 -6 9 1 -6 9 3 -1 5 3 -1 5 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 3 -3 0 -3 3 -3 0 -3 3 -3 0 -3 3 -3 0 -3 3 -3 0 -3 3 -5 3 3 -5 3 3 -5 3 3 -5 3 3 -9 4 -3 0 -4 4 -5 9Cluster # 1 2 3 4 5 6 7 8